- EMA Starts New Review of Risks with High-strength Estradiol-containing Creams
- FDA Grants Accelerated Approval to Erdafitinib for Metastatic Urothelial Carcinoma
- FDA Expands Pembrolizumab Indication for First-line Treatment of NSCLC (TPS ≥1%)
- First-line Durvalumab Improves Survival Compared to Chemotherapy in Metastatic NSCLC
- Maintenance immunotherapy fails to improve survival in extensive small cell lung cancer [ELCC Press Release]
- PROs Were Consistent with the ITT Population Across PD-L1 Subgroups in Patients with Stage III NSCLC Receiving Durvalumab or Placebo
Providing practical opinion to support best practice for busy healthcare professionals